DUBLIN, Apr. 14, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/3wkb79/liquid_biopsy_an) has announced the addition of the "Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management " report to their offering.
Cancer diagnostics based on measuring biomarkers in tissue samples has already in the past decade provided revolutionary advances in diagnosis, prognosis, and therapy selection. A major drawback of the tissue-based approach centers on the need for invasive surgical procedures in sample collection, which in a great many instances preclude following the progression or regression of disease during therapy.
In recent years, an impressive number of cancer biomarker researchers have turned their attention to the analysis of markers present in biological fluids, which can be collected with minimal invasiveness and permit following the disease over time. This highly dynamic field has come to be called liquid biopsy. In the past few years a significant and growing number of startups and several major companies have taken up the challenge of commercializing and offering liquid biopsy products and services to the market
These procedures, for the most part, query blood samples for information to be gleaned from circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) fragments, and extracellular vesicles (EVs). CTCs have the longest history as subjects for liquid biopsy. Indeed, one decade-old commercial product has already garnered FDA approval for in vitro diagnostic use. Circulating tumor DNA, a more recent entry on the liquid biopsy scene, is fast becoming an alternative or adjunct to CTC assays. EVs are the newest and least developed of the three liquid biopsy sample sources, and while highly promising, their ultimate value has yet to be fully established.
Companies active in CTCs include AdnaGen, Angle, ApoCell, Biocept, Biofluidica, Clearbridge Biomedics, Cynvenio, Cytolumina, CytoTrack, Diagnologix, Epic Sciences, Fluxion Biosciences, iCellate, Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, and SRI International. Biocept and Cynvenio exemplify companies that augment their CTC assays with ctDNA analysis.
Companies focused on ctDNA include Agena Bioscience, Boreal Genomics, Chronix Biomedical, Genomic Health, Guardant Health, Inivata, Molecular MD, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, and Trovagene.
Those active in the EV segment include Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.
Key Topics Covered:
1. Executive Summary
3. Background and History
4. Liquid Biopsy Research
5. Commercial Aspects of Liquid Biopsy
6. Market Dynamics
7. Liquid Biopsy Trends
8. Interview Transcripts
For more information visit http://www.researchandmarkets.com/research/3wkb79/liquid_biopsy_an
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets